Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
The Social Adaptation Self-evaluation Scale (SASS) is a 21-item newly developed scale for the evaluation of patient social motivation and behaviour in depression. The scale was submitted to a validation procedure based on the data from a general population survey in 4000 individuals and from two controlled studies comparing the new selective noradrenaline reuptake inhibitor (NARI), reboxetine, with placebo and/or fluoxetine in 549 patients with major depression. The scale was shown to be valid, reliable and sensitive to change. The results of the multivariate analyses allowed the identification of three principal factors and five clusters. In view of its simplicity of use, and of its peculiar characteristic of investigating patient perspective on self and environment perception and on social motivation and behaviour, the scale represents a useful additional tool for the evaluation of social functioning in depression and will facilitate the development of new antidepressants with differential effects in this domain in depressed patients.
Bosc
M
M
Pharmacia and Upjohn Medical Department, Paris, France.
Dubini
A
A
Polin
V
V
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D015203:Reproducibility of Results; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012919:Social Behavior; D011795:Surveys and Questionnaires
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D005473:Fluoxetine; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors